SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Gabe Fernandez who wrote (736)5/6/1998 8:48:00 AM
From: wolfdog2  Respond to of 1491
 
Gabe, don't look at share price when evaluating biotechs. You need to look at market cap (shares outstanding x price + total debt). On that basis PARS is still cheap, but the $3 price (it should only stay there) is misleading unless seen in the context of the number of shares outstanding.

Also when responding to Lady, please send your messages to her, not me. She might miss your message otherwise. <g>


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News